O-4310

The drug is said to be a serotonin 5-HT_2A receptor agonist and to be highly selective for activation of this receptor over the closely related serotonin 5-HT_2B and 5-HT_2C receptors.^[2] Its EC₅₀Tooltip half-maximal effective concentration at the serotonin 5-HT_2A receptor was reported to be 5 nM and it was said to have an E_maxTooltip maximal efficacy of 89% relative to serotonin.^[2] Conversely, O-4310 was said to be inactive at the serotonin 5-HT_2B receptor, with no EC₅₀ or E_max reported for this receptor, and was claimed to have an EC₅₀ of 592 nM at the serotonin 5-HT_2C receptor with an E_max of approximately 50%.^[2] Hence, O-4310 appears to show about 118-fold selectivity for activation of the serotonin 5-HT_2A receptor over the serotonin 5-HT_2C receptor.^[2]

The pharmacodynamic activity of O-4310 was briefly described in a patent but not in the published scientific literature.^[2][1] If the reported data are accurate, O-4310, along with other drugs like 25CN-NBOH and (S,S)-DMBMPP, would be one of the most selective known agonists of the serotonin 5-HT_2A receptor over the other serotonin 5-HT₂ receptors.^[3]

O-4310 was patented by Bryan Roth and colleagues in 2006 and the patent was assigned to the American pharmaceutical company Organix Inc.^[2] The drug was also employed in an animal study and described in the scientific literature by a group of Iranian researchers in 2017.^[1]

• Substituted tryptamine
• 1-Methyltryptamine
• 1-Methylpsilocin
• 1-Propyl-5-MeO-AMT
• Lespedamine (1-methoxy-DMT)
• 6-Fluoro-DMT
• SCHEMBL5334361
• 7-F-5-MeO-MET